The Pennsylvania House of Representatives on Thursday passed a bill to ban the sale of tianeptine, a synthetic opioid-like compound marketed as a dietary supplement but linked to severe health risks, according to legislative sources. The measure, which now moves to the state Senate, aims to curb the drug’s proliferation in convenience stores and online retailers.
The legislation follows growing concerns over tianeptine’s role in the state’s opioid epidemic. The U.S. Food and Drug Administration (FDA) has warned that the substance, not approved for medical use, can cause addiction, respiratory depression, and overdose. “Tianeptine’s dangerous effects mirror those of opioids, yet it remains unregulated,” said a Pennsylvania Department of Health official, citing data from 2023.
What is Tianeptine?
Tianeptine is a compound originally developed in the 1980s as an antidepressant but never approved by the FDA for human use. It is often sold online and in gas stations under names like “research chemical” or “plant food,” despite its opioid-like effects. The FDA has documented over 1,200 adverse event reports since 2020, including 23 fatal overdoses, according to a 2023 public health alert.
“This drug is a public health emergency,” said Dr. Sarah Lin, a toxicologist at the University of Pittsburgh Medical Center. “It’s being marketed as safe, but it’s not. People are dying because they don’t realize it’s a powerful opioid.”
Legislative Response and Public Health Context
The bill, introduced by Rep. Michael Torres (D-Philadelphia), would classify tianeptine as a Schedule I controlled substance, prohibiting its sale and distribution. It includes exemptions for medical research but bars commercial use. The measure aligns with similar actions in 14 states, including Ohio and Michigan, which have already banned the drug.
Public health officials note that tianeptine’s accessibility has surged in recent years. A 2023 report by the Pennsylvania Poison Center found a 300% increase in calls related to the substance compared to 2020. “It’s being sold in gas stations, online, and even in some pharmacies,” said Dr. Lin. “This bill is a critical step to close those loopholes.”
What Happens Next?
The bill’s next phase depends on the Senate’s schedule, though it faces potential opposition from some lawmakers who argue it could harm legitimate research. A spokesperson for the Pennsylvania Pharmacists Association declined to comment, citing ongoing discussions.
If passed, the law would take effect 90 days after enactment. Advocacy groups have urged swift action, pointing to data showing tianeptine-related deaths in Pennsylvania rose by 18% in 2023. “This isn’t just about regulation—it’s about saving lives,” said a representative from the Pennsylvania Harm Reduction Coalition.
As the state legislature moves forward, the bill’s success will hinge on enforcement and public awareness. Health officials warn that without stringent measures, tianeptine could continue to fuel the opioid crisis. “We can’t wait for more tragedies,” said Dr. Lin. “This is a moment to act.”
Have questions about the bill or tianeptine’s risks? Share your thoughts below or on social media using #PennsylvaniaOpioidBan.
